PS
REGN icon

Principal Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Principal Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$641K Buy
1,028
+78
+8% +$53.1K 0.01% 971
2026
Q1 		$734K Buy
950
+98
+12% +$75K 0.01% 825
2025
Q4 		$658K Sell
852
-110
-11% -$74.7K 0.01% 830
2025
Q3 		$541K Buy
962
+4
+0.4% +$2.26K 0.01% 882
2025
Q2 		$503K Buy
958
+60
+7% +$33.5K 0.01% 855
2025
Q1 		$640K Hold
898
– – 0.01% 691
2024
Q4 		$640K Buy
898
+274
+44% +$230K 0.01% 686
2024
Q3 		$656K Buy
624
+140
+29% +$156K 0.02% 672
2024
Q2 		$509K Buy
484
+112
+30% +$109K 0.01% 696
2024
Q1 		$358K Buy
372
+53
+17% +$50.4K 0.01% 797
2023
Q4 		$280K Buy
+319
New +$263K 0.01% 813

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Principal Securities's REGN Position: Q2 2026 in Review

Principal Securities increased its Regeneron Pharmaceuticals (REGN) stake by 8.2% in Q2 2026, buying an estimated $53.1K and bringing the position to 1,028 shares worth $641K. The position accounts for 0.01% of the portfolio, ranked #971.

Principal Securities first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $734K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Principal Securities held 1,028 shares of Regeneron Pharmaceuticals worth $641K as of Q2 2026.
  • Principal Securities bought 78 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $53.1K.
  • Regeneron Pharmaceuticals made up 0.01% of Principal Securities's portfolio in Q2 2026, its #971 holding.
  • Principal Securities first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Principal Securities's Regeneron Pharmaceuticals position peaked at $734K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.